PNH occurs due to defect in:
**Question:** PNH occurs due to defect in:
A. Granulocyte colony-stimulating factor (G-CSF)
B. Erythropoietin
C. Stem cell factor (SCF)
D. Interleukin-3 (IL-3)
**Correct Answer:** **D. Interleukin-3 (IL-3)**
**Core Concept:** PNH, or Paroxysmal Nocturnal Hemoglobinuria, is a rare clonal hematopoietic stem cell disorder characterized by the presence of abnormal red blood cells and platelets with deficient surface glycosylation proteins. This results in hemolysis, anemia, and thrombocytopenia.
**Why the Correct Answer is Right:** Interleukin-3 (IL-3) plays a crucial role in the development and survival of hematopoietic stem cells. In PNH, there is a deficiency in the production of glycosylphosphatidylinositol (GPI)-anchored proteins, including CD55 and CD59, which protect red blood cells (RBCs) from lysis by complement. As a result of IL-3 deficiency, the survival and proliferation of hematopoietic stem cells are impaired, leading to the development of PNH.
**Why Each Wrong Option is Incorrect:**
A. Granulocyte colony-stimulating factor (G-CSF) is involved in the differentiation, proliferation, and survival of neutrophils, not erythropoiesis or platelets, which are primarily regulated by IL-3 and erythropoietin (EPO).
B. Erythropoietin (EPO) mainly regulates erythropoiesis, the production of red blood cells, but not the survival and proliferation of hematopoietic stem cells or the production of GPI-anchored proteins.
C. Stem cell factor (SCF) is involved in the proliferation and differentiation of hematopoietic stem cells, but not the survival and production of GPI-anchored proteins, which are regulated by IL-3.
**Clinical Pearl:** Understanding the role of IL-3 in PNH is essential for accurate diagnosis and management. PNH patients require close monitoring and supportive care with transfusion and/or erythropoiesis-stimulating agents, depending on the severity of anemia and thrombocytopenia. In severe cases, these patients may require immunosuppressive therapy to prevent hemolysis due to autoimmune reactions or hemolysis from complement activation.